AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24622120 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 serial measurement
Number of subjects: 151
Study 24622120 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement of sST2, GDF-15, and hsTnT
Number of subjects: 151
Study 24340150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary free-tissue graft reconstruction
Number of subjects: 6
Study 24340150 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary free-tissue graft reconstruction
Number of subjects: 6
Study 20636654 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey 1 (factual information about harm reduction services)
Number of subjects: 260
Study 20636654 — intervention group
Group type: COMPARATOR
Intervention: Survey 2 (no information about harm reduction services, framed heroin use as problematic)
Number of subjects: 260
Study 19039893 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 404
Study 16671258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (100 microg x Kg(-1))
Number of subjects: 3
Study 16671258 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg x Kg(-1)) followed by Mivacurium (100 microg x Kg(-1))
Number of subjects: 3
Study 16671258 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg x Kg(-1)) preceded by Mivacurium (10 microg x Kg(-1)) and followed by Mivacurium (100 microg x Kg(-1))
Number of subjects: 3
Study 12858075 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy
Number of subjects: 0
Study 12858075 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive therapies (corticosteroids, antiplatelet drugs, immunosuppressive agents)
Number of subjects: 0
Study 11357697 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubled semitendinosus tendon (SET-group)
Number of subjects: 40
Study 11357697 — intervention group
Group type: COMPARATOR
Intervention: Patellar ligament graft (BTB-group)
Number of subjects: 40
Study 9183482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 123
Study 9183482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 9183482 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solutions (ORS)
Number of subjects: 123
Study 9183482 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rehydration
Number of subjects: 123
Study 8384818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 164
Study 8384818 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 164
Study 2419292 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CTX) followed by standard treatment (STD RX)
Number of subjects: 83
Study 2419292 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (STD RX; preoperative irradiation and radical excision or irradiation alone)
Number of subjects: 83
Study 2419292 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CTX)
Number of subjects: 83
Study 2419292 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (STD RX)
Number of subjects: 83
Study 28543751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program with pelvic floor muscle contraction
Number of subjects: 50
Study 28543751 — intervention group
Group type: COMPARATOR
Intervention: Control group (walking and strengthening exercises)
Number of subjects: 50
Study 27768966 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D ultrasound (n=258)
Number of subjects: 410
Study 27768966 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasound (n=152)
Number of subjects: 410
Study 27768966 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall measurements
Number of subjects: 410
Study 25421518 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1146
Study 25421518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1146
Study 25421518 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment dropouts (n=185)
Number of subjects: 1146
Study 22627121 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant application (FS+)
Number of subjects: 78
Study 22627121 — intervention group
Group type: COMPARATOR
Intervention: No fibrin sealant application (FS-)
Number of subjects: 78
Study 20127419 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment with ACE medication
Number of subjects: 507
Study 20127419 — intervention group
Group type: COMPARATOR
Intervention: ICD treatment without ACE medication
Number of subjects: 507
Study 19100422 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium, calcitriol, and alendronate
Number of subjects: 46
Study 19100422 — intervention group
Group type: COMPARATOR
Intervention: calcium and calcitriol
Number of subjects: 46
Study 15790985 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 1465
Study 15790985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg twice daily
Number of subjects: 1465
Study 15790985 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination 50/500 microg twice daily
Number of subjects: 1465
Study 15790985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1465
Study 11551005 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire + Solid Bond
Number of subjects: 16
Study 11551005 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERT + Bond‐1
Number of subjects: 16
Study 11551005 — intervention group
Group type: EXPERIMENTAL
Intervention: Surefil + Prime & Bond NT
Number of subjects: 16
Study 11551005 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek P60 + Single Bond
Number of subjects: 16
Study 11551005 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH Spectrum + Prime & Bond 2.1
Number of subjects: 16
Study 9763554 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA followed by chemotherapy (CT)
Number of subjects: 413
Study 7828253 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with meperidine (Group 1)
Number of subjects: 75
Study 7828253 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine with saline PCEA (Group 2)
Number of subjects: 75
Study 7828253 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine without saline PCEA (Group 3)
Number of subjects: 75
Study 7828253 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural meperidine (Group 1)
Number of subjects: 75
Study 2969638 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day of HPR
Number of subjects: 101
Study 2969638 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of HPR
Number of subjects: 101
Study 2969638 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of HPR
Number of subjects: 101
Study 2969638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 1385959 — intervention group
Group type: EXPERIMENTAL
Intervention: Niceritrol 1.5 g daily for 12 weeks (b.i.d.)
Number of subjects: 33
Study 1385959 — intervention group
Group type: EXPERIMENTAL
Intervention: Niceritrol 1.5 g daily for 12 weeks (t.i.d.)
Number of subjects: 33
Study 1385959 — intervention group
Group type: EXPERIMENTAL
Intervention: Niceritrol in patients with initially high Lp(a) (≥20 mg/dl)
Number of subjects: 33
Study 356507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.05 mg/kg body weight)
Number of subjects: 28
Study 356507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study 31154298 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alert containing an AKI-specific order set
Number of subjects: 6030
Study 31154298 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6030
Study 28349233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 10 mg orally twice daily for 8 weeks
Number of subjects: 20
Study 28349233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28349233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 20
Study 28349233 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) and Placebo
Number of subjects: 20
Study 25308290 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 490
Study 25308290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored hand exercises
Number of subjects: 490
Study 25308290 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 490
Study 25308290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of tailored hand exercise
Number of subjects: 490
Study 23642329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4)
Number of subjects: 546
Study 23642329 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4) plus placebo
Number of subjects: 546
Study 23642329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine
Number of subjects: 546
Study 23642329 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 546
Study 23642329 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg every 2 weeks)
Number of subjects: 546
Study 21644984 — intervention group
Group type: EXPERIMENTAL
Intervention: Full CBT (12 sessions)
Number of subjects: 96
Study 21644984 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief CBT (5 sessions with therapist-guided workbooks)
Number of subjects: 96
Study 21644984 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 96
Study 19661781 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Number of subjects: 1227
Study 19661781 — intervention group
Group type: EXPERIMENTAL
Intervention: Node negative patients with 7 or less lymph nodes examined
Number of subjects: 1227
Study 17503976 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 461
Study 17503976 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/day
Number of subjects: 461
Study 17503976 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/day
Number of subjects: 461
Study 17503976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 15204513 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (treatment group)
Number of subjects: 36
Study 15204513 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 36
Study 11182866 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step focused group treatment
Number of subjects: 132
Study 11182866 — intervention group
Group type: COMPARATOR
Intervention: Individualized relapse prevention continuing care
Number of subjects: 132
Study 9644283 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of advance information
Number of subjects: 26
Study 9644283 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate levels of advance information
Number of subjects: 26
Study 9644283 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of advance information
Number of subjects: 26
Study 8162480 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy for chronic low back pain (3-week therapy programme)
Number of subjects: 102
Study 8162480 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory care for chronic low back pain
Number of subjects: 102
Study 8162480 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy for chronic low back pain (9 months follow-up)
Number of subjects: 102
Study 3227043 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 210 mg
Number of subjects: 0
Study 3227043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3227043 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 15-30 mg
Number of subjects: 0
Study 31120541 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructans from Ophiopogon japonicus
Number of subjects: 234
Study 31120541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 28262186 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine methanol concentration on hangover days
Number of subjects: 36
Study 28262186 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine methanol concentration in hangover group
Number of subjects: 36
Study 28262186 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine methanol concentration in hangover-immune group
Number of subjects: 36
Study 28262186 — intervention group
Group type: COMPARATOR
Intervention: Urine methanol concentration in hangover group vs hangover-immune group
Number of subjects: 36
Study 26791800 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiemetic therapy with aprepitant, palonosetron, and dexamethasone
Number of subjects: 80
Study 26791800 — intervention group
Group type: COMPARATOR
Intervention: Double antiemetic therapy with palonosetron and dexamethasone
Number of subjects: 80
Study 23816610 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ASA + ERDP)
Number of subjects: 14676
Study 23816610 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 14676
Study 20581703 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional (TD) strength training
Number of subjects: 42
Study 20581703 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly undulating (WUD) strength training
Number of subjects: 42
Study 20581703 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 42
Study 18084048 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hLH (Luveris, 300 IU/day) for 7 days
Number of subjects: 146
Study 18084048 — intervention group
Group type: COMPARATOR
Intervention: No r‐hLH treatment
Number of subjects: 146
Study 18084048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 16938136 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphora‐Psy questionnaire
Number of subjects: 728
Study 16938136 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of Care questionnaire
Number of subjects: 728
Study 16938136 — intervention group
Group type: EXPERIMENTAL
Intervention: Picker Institute questionnaire
Number of subjects: 728
Study 14618034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 200
Study 14618034 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 200
Study 14618034 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 200
Study 14618034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm
Number of subjects: 200
Study 11693741 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning (5 min ischemia/5 min reoxygenation before 90 min ischemia/120 min reoxygenation)
Number of subjects: 42
Study 11693741 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (Mito KATP opener, 0.1 mm for 10 min before 90 min ischemia/120 min reoxygenation)
Number of subjects: 42
Study 11693741 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (10 microm for 10 min exposure prior to PC in diabetic patient groups)
Number of subjects: 42
Study 11693741 — intervention group
Group type: COMPARATOR
Intervention: Ischemia alone (90 min ischemia followed by 120 min reoxygenation)
Number of subjects: 42
Study 11693741 — intervention group
Group type: COMPARATOR
Intervention: Aerobic control (incubated in oxygenated buffer for 210 min)
Number of subjects: 42
Study 15321242 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 % bupivacaine plus 50 microg fentanyl
Number of subjects: 24
Study 15321242 — intervention group
Group type: COMPARATOR
Intervention: 0.5 % bupivacaine
Number of subjects: 24
Study 7868662 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182,780, 12 mg daily for 7 days
Number of subjects: 17
Study 7868662 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 normal women)
Number of subjects: 17
Study 7868662 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 182,780 treatment group
Number of subjects: 17
Study 7868662 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 7868662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study 3044182 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg/kg diltiazem before induction of anesthesia
Number of subjects: 60
Study 3044182 — intervention group
Group type: COMPARATOR
Intervention: 0.014 mg diltiazem/kg per min over 20 min before cannulation
Number of subjects: 60
Study 3044182 — intervention group
Group type: COMPARATOR
Intervention: 0.014 mg diltiazem/kg per min during ECC
Number of subjects: 60
Study 31475385 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach proposed by VanderWeele et al (2014) for decomposing total causal effect under three scenarios.
Number of subjects: 0
Study 31475385 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended approach to multiple mediators influenced by exposure-induced mediator-outcome confounder.
Number of subjects: 0
Study 27770483 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate birth
Number of subjects: 1835
Study 27770483 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1835
Study 25487069 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' attitudes toward patients with schizophrenia with bizarre affect (SBA)
Number of subjects: 256
Study 25487069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management decisions
Number of subjects: 256
Study 25487069 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data on trust and engagement
Number of subjects: 256
Study 25487069 — intervention group
Group type: EXPERIMENTAL
Intervention: Colleague alerts about SBA
Number of subjects: 256
Study 23755765 — intervention group
Group type: EXPERIMENTAL
Intervention: Levico and Vetriolo arsenical-ferruginous water
Number of subjects: 34
Study 23755765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21330912 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-dose nevirapine
Number of subjects: 1890
Study 21330912 — intervention group
Group type: COMPARATOR
Intervention: Single-dose nevirapine
Number of subjects: 1890
Study 21330912 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-dose nevirapine (for mothers with CD4 > 350 cells/μl)
Number of subjects: 1890
Study 19826272 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg/kg/d, max 1.98 mg/kg/d in six divided doses)
Number of subjects: 79
Study 19826272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 79
Study 16400058 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg I (as oral iodized oil)
Number of subjects: 310
Study 16400058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 15249521 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication training
Number of subjects: 747
Study 15249521 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM training
Number of subjects: 747
Study 15249521 — intervention group
Group type: EXPERIMENTAL
Intervention: Research clinics (more time for consultations)
Number of subjects: 747
Study 11417301 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-endothelial cell antibody (AECA) titer measurement in renal transplant recipients with acute rejection (n = 27)
Number of subjects: 58
Study 11417301 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-endothelial cell antibody (AECA) titer measurement post-rejection therapy
Number of subjects: 58
Study 11417301 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AECA titers in hemodialysis patients vs. healthy controls
Number of subjects: 58
Study 11417301 — intervention group
Group type: COMPARATOR
Intervention: AECA titer measurement in transplant recipients by dialysis mode
Number of subjects: 58
Study 11417301 — intervention group
Group type: EXPERIMENTAL
Intervention: AECA titer measurement pre- and post-renal transplantation
Number of subjects: 58
Study 11417301 — intervention group
Group type: EXPERIMENTAL
Intervention: AECA titer in recipients with acute rejection
Number of subjects: 58
Study 9180323 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (group B)
Number of subjects: 39
Study 9180323 — intervention group
Group type: COMPARATOR
Intervention: Cast immobilisation (group A)
Number of subjects: 39
Study 1288238 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg per day for 6 months)
Number of subjects: 389
Study 1288238 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravesical chemoprophylaxis only)
Number of subjects: 389
Study 3834100 — intervention group
Group type: EXPERIMENTAL
Intervention: Program model considering clinical decision making based on patient characteristics, intensity of care, and treatment modalities
Number of subjects: 0
Study 3834100 — intervention group
Group type: COMPARATOR
Intervention: Inpatient model
Number of subjects: 0
Study 3834100 — intervention group
Group type: COMPARATOR
Intervention: Outpatient model
Number of subjects: 0
Study 30496529 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch (ES)
Number of subjects: 191
Study 30496529 — intervention group
Group type: COMPARATOR
Intervention: Non-endometrial scratch (non-ES)
Number of subjects: 191
Study 30515482 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group (IL)
Number of subjects: 20
Study 30515482 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading group (DL)
Number of subjects: 20
Study 27919589 — intervention group
Group type: EXPERIMENTAL
Intervention: M + R (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg)
Number of subjects: 80
Study 27919589 — intervention group
Group type: EXPERIMENTAL
Intervention: M + R + K (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg)
Number of subjects: 80
Study 27919589 — intervention group
Group type: EXPERIMENTAL
Intervention: M + R + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + naloxone 2 μg)
Number of subjects: 80
Study 27919589 — intervention group
Group type: EXPERIMENTAL
Intervention: M + R + K + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg + naloxone 2 μg)
Number of subjects: 80